The FDA has approved Johnson & Johnson’s Inlexzo (gemcitabine intravesical system), introducing the first drug-releasing bladder insert for adults with high-risk, non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG) therapy. Approved on September 9, 2025, Inlexzo provides a much-needed, bladder-sparing alternative for patients who cannot or do not wish to pursue radical cystectomy (bladder removal surgery).
Inlexzo works by delivering low-dose gemcitabine directly into the bladder via a device that can remain in place for three weeks per cycle and up to 14 cycles total. This outpatient treatment offers cancer control with minimal disruption to daily life and does not require general anesthesia. Clinical trial results were striking: 82% of patients achieved a complete response at three months, and more than half remained cancer-free at one year.
"For patients facing the possibility of life-altering bladder removal after BCG failure, Inlexzo is a landmark advancement,” said Sia Daneshmand, MD, a lead investigator in the SunRISe-1 trial. J&J will support patient access through its withMe program, offering cost support and resources.
This FDA nod marks the first major innovation for BCG-unresponsive NMIBC in decades and is set to transform treatment pathways for bladder cancer patients.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!